Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Fipaxalparant by Amgen for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Fipaxalparant is under clinical development by Amgen and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...
Data Insights
Fipaxalparant by Horizon Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Fipaxalparant is under clinical development by Horizon Therapeutics and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData,...